Blog

The Board of Directors Urges Shareholders to Vote by October 31, 2025 at 11:59 p.m., Central Time on Proxy Proposals

ISS Recommends Shareholders Vote “FOR” on all Proposals

FRISCO, TEXAS / ACCESS Newswire / October 21, 2025 / GameSquare Holdings, Inc. (“GameSquare” or the “Company”) announced that it has rescheduled its Annual Meeting of Shareholders (the “Annual Meeting”) until November 4, 2025. The Annual Meeting was adjourned to provide shareholders with additional time to vote.

Institutional Shareholder Services (ISS), an industry leading independent proxy advisory firm, has recommended that GameSquare’s shareholders vote “FOR” the Company’s four proposals, including approval of the merger agreement with the Company’s wholly owned subsidiary for the purpose of restating the Certificate of Incorporation to, among other things, increase the number of authorized shares, eliminate supermajority voting requirements to amend the Certificate of Incorporation, declassify the Board of Directors, and implement other non-material specified changes.

Insiders and major shareholders, including the Jones and Goff families, members of management and board, Ryan Zurrer and Robert Leshner, have all voted in favor of the Company’s proposals, demonstrating their continued confidence in the Company’s strategy and long-term potential.

YOUR VOTE IS IMPORTANT NO MATTER HOW MANY SHARES YOU HOLD.

FOR ASSISTANCE WITH VOTING CONTACT Laurel Hill Advisory Group at 1-888.742.1305, or International at +1-416-304-0211, or email Jdepinto@laurelhill.com.

“We’ve received strong support from many of our shareholders, as well as ISS, widely recognized as the industry’s leading independent proxy advisory firm. This underscores the strong merit of our proposals and the value they bring to shareholders,” said Justin Kenna, CEO of GameSquare.

“A number of shareholders have already voted in favor of GameSquare’s proposals, but we need more shareholders to vote. The proposals are designed to position GameSquare for continued growth and value creation as we execute our vision for the future. Every vote matters, and I encourage all shareholders to take a few minutes to vote their shares today and make their voice heard,” Kenna concluded.

Shareholders of record as of September 5, 2025, are advised to vote their shares well in advance of the proxy voting deadline of 11:59 p.m. CT, on October 31, 2025. The proposals are included in the definitive proxy statement filed with the U.S. Securities and Exchange Commission on September 8, 2025. The proxy statement is available at: https://www.sec.gov/ix?doc=/Archives/edgar/data/1714562/000164117225026855/formdef14a.htm

THE BOARD OF DIRECTORS RECOMMENDS THAT SHAREHOLDERS VOTE FOR ALL DIRECTOR NOMINEES AND PROPOSED RESOLUTIONS.

Key Proxy Proposal: Technical Statutory Merger
The primary proposal this year is the approval of a statutory merger with a wholly owned subsidiary. GameSquare will remain the surviving entity. This is a technical reorganization only and not a new merger or acquisition. The purpose of the merger is to adopt a restated set of articles of incorporation.

Approval of this proposal will allow GameSquare to:

• Modernize and simplify its governing documents

• Provide flexibility to support future growth and capital markets initiatives

• Align its governance framework with current best practices

Other Proxy Proposals
In addition to the statutory merger, shareholders are being asked to consider:

• Election of Directors with the expertise to provide strong oversight and leadership

• Ratification of Independent Auditors to reinforce confidence in GameSquare’s financial reporting

• Equity and Governance Matters that support attracting and retaining talent, aligning management incentives with shareholders, and strengthening corporate governance

Your Vote Matters
Every shareholder’s vote is important, regardless of the number of shares owned. Shareholders are strongly encouraged to vote as soon as possible online, by telephone, or by mailing their proxy card, as outlined in the proxy materials.

Shareholder Questions and Voting Assistance
Shareholders who have any questions or require assistance with voting may contact the Company’s proxy solicitation agent and shareholder communications advisor:

Laurel Hill Advisory Group
Toll Free (North America): 1-888.742.1305
International: +1-416-304-0211
By Email: Jdepinto@laurelhill.com

About GameSquare Holdings, Inc.
GameSquare (NASDAQ:GAME) is a cutting-edge media, entertainment, and technology company transforming how brands and publishers connect with Gen Z, Gen Alpha, and Millennial audiences. With a platform that spans award-winning creative services, advanced analytics, and FaZe Clan Esports, one of the most iconic gaming organizations, we operate one of the largest gaming media networks in North America. As a digital-native business, GameSquare provides brands with unparalleled access to world-class creators and talent, delivering authentic connections across gaming, esports, and youth culture. Complementing our operating strategy, GameSquare has developed an innovative treasury management program designed to generate yield and enhance capital efficiency, reinforcing our commitment to building a dynamic, high-performing media company at the intersection of culture, technology, and next-generation financial innovation.

To learn more, visit www.gamesquare.com.

Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the Company’s future performance, returns generated by its business strategies, revenue, growth and profitability; and the Company’s ability to execute on its current and future business plans. These forward-looking statements are provided only to provide information currently available to us and are not intended to serve as and must not be relied on by any investor as, a guarantee, assurance or definitive statement of fact or probability. Forward-looking statements are necessarily based upon a number of estimates and assumptions which include, but are not limited to: the Company’s 2025 annual meeting of shareholders (the “Annual Meeting”) and corporate governance, the Company’s ability to grow its business and being able to execute on its business plans and strategies, the success of Company’s vendors and partners in their provision of services to the Company, the Company being able to recognize and capitalize on opportunities and the Company continuing to attract qualified personnel to supports its development requirements. These assumptions, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: the Company’s annual meeting and corporate governance, its ability to achieve its objectives, the Company successfully executing its growth strategy, the ability of the Company to obtain future financings or complete offerings on acceptable terms, failure to leverage the Company’s portfolio across entertainment and media platforms, dependence on the Company’s key personnel and general business, economic, competitive, political and social uncertainties. These risk factors are not intended to represent a complete list of the factors that could affect the Company which are discussed in the Company’s most recent MD&A. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. GameSquare assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Corporate Contact
Lou Schwartz, President
Phone: (216) 464-6400
Email: ir@gamesquare.com

Investor Relations
Andrew Berger
Phone: (216) 464-6400
Email: ir@gamesquare.com

Media Relations
Chelsey Northern / The Untold
Phone: (254) 855-4028
Email: pr@gamesquare.com

SOURCE: GameSquare Holdings, Inc.

View the original press release on ACCESS Newswire

Matey and the South Carolina Association of Criminal Defense Lawyers (SCACDL) announce an exclusive partnership to bring trusted, transparent AI eDiscovery tools to defense attorneys across South Carolina, helping criminal defense lawyers quickly organize discovery, analyze evidence, and prepare stronger cases with secure, citation-based technology.

AUSTIN, TEXAS / ACCESS Newswire / October 21, 2025 / Matey, the AI platform designed to help legal professionals save time and strengthen case preparation, is proud to announce a new partnership with the South Carolina Association of Criminal Defense Lawyers (SCACDL). Through this collaboration, Matey becomes SCACDL’s exclusive AI partner for eDiscovery, supporting defense attorneys across South Carolina with trusted, transparent technology.

The partnership reflects a shared mission to advance the practice of criminal defense through innovation and integrity. As part of the collaboration, Matey will participate in SCACDL-hosted events throughout the year, providing hands-on demonstrations, educational sessions, and practical guidance on how AI can help attorneys efficiently organize discovery, review evidence, and prepare with confidence for court.

“We’re truly honored to partner with SCACDL,” said Jaime Donoahue, Director of Partnerships & Outreach, Matey. “We’ve gotten to know the SCACDL community and really appreciate the heart and dedication of its members. Being around such passionate defense attorneys has been a joy, and we’re excited to keep showing up, supporting their work, and helping them bring trusted AI into their practice with confidence.”

Matey’s secure AI platform helps attorneys identify key information across videos, audio, and transcripts, verify outputs through citations and audit logs, and collaborate effectively across teams. Each insight is backed by citations and reviewability, ensuring lawyers can trust the results in their casework.

“This collaboration reinforces SCACDL’s commitment to providing our members with innovative, reliable resources that support their work in and out of the courtroom,” said Kitty Sutton, Executive Director, SCACDL. “Matey’s approach to eDiscovery aligns perfectly with our focus on professionalism, accuracy, and client advocacy.”

Together, SCACDL and Matey are setting a new standard for how defense attorneys can leverage AI responsibly – combining efficiency with the trust and accountability essential to criminal defense.

For more information, visit www.matey.ai or www.scacdl.org.

Contact Information

Jason Whitson
COO
jason@matey.ai

Jaime Donoahue
Director of Partnerships & Outreach
jaime.donoahue@matey.ai

SOURCE: Matey

View the original press release on ACCESS Newswire

Reform Metrics and Global Outlook Underpin London Gathering

LONDON, UK / ACCESS Newswire / October 22, 2025 / The Sultanate of Oman, represented by the Ministry of Finance in cooperation with the Ministry of Foreign Affairs, held the Oman Investment Forum 2025 in London to deepen financial, investment, and economic cooperation between the two nations. The event underscored the strategic weight of the Oman-UK partnership and the role of the Strategic Advisory Group (SAG), established in 2018 as the institutional mechanism through which the two countries coordinate investment, fiscal reform, and economic-diversification strategy.

Oman enters this year’s forum with one of the strongest fiscal positions in the region. Foreign Direct Investment (FDI) reached USD 78.8 billion by the end of the second quarter of 2025, a 12.8 percent increase compared to 2024. Inflows during the first half of 2025 totalled USD 8.8 billion, reflecting rising international confidence.

Omani officials opened the forum by highlighting progress in stabilizing public finances and diversifying the economy. The government’s fiscal discipline has sharply reduced public debt from 68 percent of GDP in 2020 to 34 percent in 2024, cutting debt-service costs by over 12 percent from peak levels. Nasser Al Jashmi, Chairman of the Tax Authority and Head of the Omani Delegation to the Strategic Advisory Group, presented “Pathways to Oman’s Financial Stability,” outlining key reforms in public finance and debt management that have strengthened the country’s fiscal resilience and global credit standing. He said, “The historical Omani-UK relations stand as a pillar of friendship and shared prosperity. This forum is a testament to the strong and enduring partnership between our two countries within the framework of the Strategic Advisory Group (SAG). The UK is currently the largest foreign investor in the Sultanate’s economy, accounting for 51.2% of total FDI, which emphasizes the importance of this forum in enhancing the growth of investments between the two countries and global investment collaboration.”

H.E. Mahmood Al Aweini, Secretary-General of the Ministry of Finance and Supervisor of the National Program for Fiscal Sustainability and Financial Sector Development (Estidamah), said: “This forum showcases the renewed international confidence in Oman’s economy and financial strength, with the presence of leading financial institutions and investment funds. This event comes after a bold journey of achievements in the public finance reform, which led to milestones in developing its financial system and managed to turn financial challenges into successes. The UK has been and continues to be a key strategic partner in achieving our mutual investment and economic interests. As we are heading into a diversified, competitive, and sustainable future, we look forward to continuing to strengthen this partnership towards the prosperity of both nations.”

He stated that “the public debt-to-GDP ratio fell from 68% in 2020 to 34% in 2024, which reduced debt service costs by more than 12% from their peak levels since 2020.”

In the first panel discussion, H.E. Ahmed Al Musalmi, Governor of the Central Bank of Oman, and H.E. Mahmood Al Aweini discussed “Financing Growth: Reforming Oman’s Financial Sector,” highlighting initiatives to strengthen the financial and banking sector and the role of debt instruments in financing growth.

H.E. Al Musalmi said: “This forum represents a pivotal moment – transforming over two centuries of Omani-British partnership into a structured platform for resilient, diversified growth. Strategically positioned at the crossroads of Asia, the Middle East, and Africa, Oman offers seamless access to over 2.5 billion consumers – powered by world-class ports, free zones, and integrated supply chains. Our shared ambition is clear: scale investable opportunities, strengthen climate and supply-chain resilience, and generate high-quality jobs – positioning Oman as a competitive regional hub and delivering enduring value for both nations.”

Mulham Al Jarf, Deputy President for Investment at the Oman Investment Authority (OIA), participated in a panel on “Advancing Oman’s Capital Markets in a Global Context.” He noted that the OIA has implemented multiple initiatives to expand the Muscat Stock Exchange since assuming ownership in 2021, achieving record growth and trading figures. He added that OIA’s participation in the forum underscores its strategic partnerships, contribution to attracting foreign investment, and its position as a partner of choice for global investors.

The forum, convened at the invitation of Sohar International Bank and HSBC, brought together senior representatives of global investment funds, financial institutions, and private-sector leaders to explore cross-border opportunities and bilateral collaboration. Parallel sessions addressed fiscal innovation, capital-market reform, and public-private investment mechanisms aligned with Oman Vision 2040. The meetings precede the thirteenth session of the Oman-UK Strategic Advisory Group, scheduled from 23 to 24 October in Cardiff, further cementing the long-standing financial and economic partnership between the two countries.

SOURCE: Strategy Lab Oman

View the original press release on ACCESS Newswire

LAFAYETTE, LA / ACCESS Newswire / October 21, 2025 / Viemed Healthcare, Inc. (the “Company” or “Viemed“) (NASDAQ:VMD), a national leader of in-home, technology-enabled post-acute respiratory care, today announced that it will host its Third Quarter 2025 Earnings Conference Call on Thursday, November 6, 2025, at 11:00 a.m. ET.

Interested parties may participate in the call by dialing:

(877) 407-6176 (US Toll-Free)

+1 (201) 689-8451 (International)

Live Audio Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=asCOlSnC

Following the live call, a replay will be available in the Investor Relations section of the Company’s website at https://www.viemed.com.

ABOUT VIEMED HEALTHCARE, INC.

Viemed is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. Viemed focuses on efficient and effective in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. Visit our website at https://www.viemed.com.

For further information, please contact:

Investor Relations
ir@viemed.com

Trae Fitzgerald
Chief Financial Officer
Viemed Healthcare, Inc.
(337) 504-3802

SOURCE: Viemed Healthcare, Inc.

View the original press release on ACCESS Newswire

JACKSONVILLE, FL / ACCESS Newswire / October 21, 2025 / FRP Holdings, Inc. (NASDAQ:FRPH) announced today that the Company has completed the closing on its Purchase and Sales Agreement to acquire the business operations and development pipeline of Altman Logistics Properties, LLC, an operating platform of BBX Capital. Altman Logistics holds minority interests in a portfolio of institutional-grade industrial assets under various stages of development (including the Company’s industrial developments in Lakeland and Broward County, FL) as well as a contract for the purchase of an industrial land parcel.

Management believes that this acquisition aligns with its growth strategy by:

• Expanding the Company’s capabilities and “bench” by adding an accomplished team of professionals with proven development and transaction expertise and established industry relationships-accelerating the talent growth that would otherwise have taken years to build organically and enhancing the ability to deliver on the ten-year investment and development strategy.

• Much needed additional resources will support the Company’s efforts to execute on existing plan to double NOI over the next five years, furthering our progress to increase FRP’s sum-of-the-parts valuation to over $1 billion upon stabilization of the five-year development pipeline.

• Enhancing deal flow and pipeline projects for both wholly owned and joint venture opportunities.

• Broadening its exposure to high-quality industrial assets in key markets.

• Giving the Company 100% ownership of the Lakeland and Davie projects by acquiring Altman’s 10% and 20% minority interests, respectively, in those projects.

Management expects that the incoming team will be fully integrated into its industrial platform over the next several months. Their market expertise and relationships will be leveraged to: advance acquisitions, manage the Company’s existing development pipeline, and optimize existing stabilized assets. The Company anticipates immediate contributions to sourcing and underwriting activity with minimal disruption to ongoing operations.

Details of the Acquisition

The purchase price was $33.5 million, which included a $10 million reimbursement to Altman for the assignment of a bank account held by a special purpose entity that is the guarantor for approximately $49 million on $121.8 million in construction debt. As a result, the net cash requirement was $23.6 million. At closing, $45.3 million of the $121.8 million in total construction financing had been drawn, resulting in a $5.2 million share of debt attributable to the Company. In addition, the Company expects to record additional liabilities related to employee compensation tied to promote participation upon stabilization and sale of the projects.

The Altman Logistics Properties model consisted of a develop and sell program whereby Altman collected development fees from its joint venture partners and held the right to a promote upon a successful sale of the project at stabilization. With respect to all the projects listed in the table below (other than Lakeland and Davie which the Company will now own 100% and intends to own those projects long-term) the Company intends to continue the Altman Logistics Properties model which the Company estimates will generate a 15-20%+ IRR at the property level prior to any promotes the Company would be entitled to receive. More importantly, the transaction adds a seasoned team of professionals from the Altman Logistics Properties platform onto the Company’s management team, strengthening its capabilities in acquisition, development, disposition and asset management, and advancing the depth, capability, and operational strength to deliver on our ten-year strategy and position the Company for sustained long-term success.

The following table details the projects purchased and the square feet (SF) of the warehouses:

City	Street Address	36′ Clear Height SF	Ownership Acquired	Status
Delray Beach, FL	14130 S State Rd. 7	199,476	10%(1)	Substantial completion Q4 2025
Delray Beach, FL	14130 S State Rd. 7	392,976	10% (1)	Land for 2 warehouses
Hamilton, NJ	600 Horizon Dr.	170,800	8.5% (1)	Substantial completion Q4 2025
Parsippany, NJ	8 Lanidex Plaza W.	140,031	10% (1)	Substantial completion Q1 2026
Lakeland, FL	8161 State Rd. 33	201,420	10% (2)	Substantial completion Q2 2026
Davie, FL	6900 W. State Rd 84	182,773	20% (2)	Substantial completion Q2 2026
		1,287,476
Southwest Ranches, FL	SW 202 nd Ave. & Sheridan St.	335,617		Land acquisition contract 2026

1. General Partner investment, distributions will be based upon waterfall model.

2. FRP already owns the remaining portion.

Management remains committed to disciplined capital allocation and pursuing opportunities that deliver sustainable value to shareholders.

FRP was advised by Arnold & Porter Kaye Scholer LLP in the transaction.

Conference Call

The Company will host a conference call on Thursday, October 23, 2025 at 1:00 p.m. (ET). Analysts, stockholders and other interested parties may access the teleconference live by calling 1-800-274-8461 (passcode 83364) within the United States. International callers may dial 1-203-518-9814 (passcode 83364). Audio replay will be available until November 6, 2025 by dialing 1-800-938-1584 within the United States. International callers may dial 1-402-220-1542. No passcode needed. An audio replay will also be available on the Company’s website under investors, events & presentations (https://investors.frpdev.com/events) following the call.

Additional Information

Our investor relations website is https://investors.frpdev.com and we encourage investors to use it as a way of easily finding information about us. We promptly make available on this website, free of charge, the reports that we file or furnish with the SEC, press releases, quarterly earnings presentations, investor presentations, and corporate governance information, which may contain material information about us, and you may subscribe to Email Alerts to be notified of new information posted to this site.

Investors are cautioned that any statements in this press release which relate to the future are, by their nature, subject to risks and uncertainties that could cause actual results and events to differ materially from those indicated in such forward-looking statements. These include, but are not limited to: the possibility that we may be unable to find appropriate investment opportunities; levels of construction activity in the markets served by our mining properties; demand for flexible warehouse/office facilities in the MidAtlantic and Florida; multifamily demand in Washington D.C. and Greenville, South Carolina; our ability to obtain zoning and entitlements necessary for property development; the impact of lending and capital market conditions on our liquidity; our ability to finance projects or repay our debt; general real estate investment and development risks; vacancies in our properties; risks associated with developing and managing properties in partnership with others; competition; our ability to renew leases or re-lease spaces as leases expire; illiquidity of real estate investments; bankruptcy or defaults of tenants; the impact of restrictions imposed by our credit facility; the level and volatility of interest rates; environmental liabilities; inflation risks; cybersecurity risks; as the impact of tariffs on our industrial tenants and construction costs; well as other risks listed from time to time in our SEC filings; including but not limited to; our annual and quarterly reports. We have no obligation to revise or update any forward-looking statements, other than as imposed by law, as a result of future events or new information. Readers are cautioned not to place undue reliance on such forward-looking statements.

FRP Holdings, Inc. is a holding company engaged in the real estate business, namely (i) leasing and management of commercial properties owned by the Company, (ii) leasing and management of mining royalty land owned by the Company, (iii) real property acquisition, entitlement, development and construction primarily for apartment, retail, warehouse, and office, and (iv) leasing and management of residential apartment buildings.

Contact:

Matthew C. McNulty
Chief Financial Officer
(904) 858-9100

SOURCE: FRP Holdings, Inc.

View the original press release on ACCESS Newswire

Company Advances Roadmap Ahead of Schedule; Expands Blockchain Applications Beyond Ticketing to Accreditation in Education and Healthcare

NEW YORK, NY AND TORONTO, ON / ACCESS Newswire / October 21, 2025 / Nextech3D.ai (CSE:NTAR)(OTCQX:NEXCF)(FSE:1SS), an AI-first technology company specializing in event management, 3D modeling, and spatial computing, is pleased to announce the launch of its Blockchain Ticketing Platform powered by Ethereum, with support for Coinbase Wallet and MetaMask.

This launch accelerates the Company’s previously announced two-track blockchain strategy, which included:

• Phase 1: a custodial wallet solution targeted for Q4 2025; and

• Phase 2: a self-custody personal wallet option originally planned for early 2026.

Thanks to Nextechs3d.ai recent acquisition of Eventdex which had already developed a personal wallet architecture, the Company is now launching the personal wallet first, ahead of schedule. This milestone strengthens Nextech3D.ai’s position as a leader in AI-driven and blockchain-secured event technology.

Secure, Decentralized Ticketing on Ethereum

The new blockchain ticketing platform enables event organizers and attendees to issue, store, and verify tickets as Ethereum-based tokens, seamlessly connected to Coinbase and MetaMask wallets. These blockchain-integrated tickets are:

• Fraud-Resistant: Immutable, traceable smart contracts eliminate duplication and counterfeit risks.

• Programmable: Organizers can embed VIP access, sponsor perks, or resale royalties directly into each ticket.

• Interoperable: Works across Ethereum-based wallets and decentralized applications.

“This launch marks a major leap forward in the event industry,” said Evan Gappelberg, CEO of Nextech3D.ai. “By combining blockchain security, wallet interoperability, and AI-driven event automation, we’re creating a frictionless ecosystem for organizers, exhibitors, and attendees. It’s not just about ticketing-it’s about trust, transparency, and value.”

Beyond Ticketing: Blockchain Accreditation

While blockchain ticketing is the first application, Nextech3D.ai sees enormous potential to extend this technology into blockchain-based accreditation and credentialing-particularly for the Company’s continuing education clients in healthcare, higher education, and professional certification.

Using the same Ethereum infrastructure, Nextech3D.ai will enable event and education customers to issue verifiable, on-chain certificates that prove attendance, accreditation, and achievement-all easily stored and shared through blockchain wallets like Coinbase and MetaMask.

“Our education and healthcare partners are already using our platforms to manage continuing education and compliance programs,” added Gappelberg. “With blockchain accreditation, we’re turning those records into verifiable digital assets-giving institutions and participants a secure, permanent record of professional growth.”

AI + Blockchain: The Future of Event and Education Technology

Nextech3D.ai’s AI Event Suite now includes:

• AI Matchmaking: Intelligent, data-driven networking to connect attendees and exhibitors.

• AI Event Assistant: A real-time, multilingual event concierge available 24/7.

• Blockchain Ticketing: Decentralized ticketing and accreditation on Ethereum with Coinbase and MetaMask wallet support.

This integrated approach positions Nextech3D.ai to lead the convergence of AI, blockchain, and automation in global event and education markets, a sector representing multi-billion-dollar opportunities.

The company has entered into agreements (the “Agreements“) with certain service providers of the Company pursuant to which the Company proposes to issue an aggregate of 3,688,218 common shares at a deemed price of Cdn$ 0.19 per share in consideration of past services and satisfaction of outstanding indebtedness

The share issuances remain subject to the approval of the Canadian Securities Exchange.

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act“) or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.

About Nextech3D.ai

Nextech3D.ai (OTCQX: NEXCF | CSE: NTAR | FSE: 1SS) is an AI-first technology company developing advanced solutions for event management, 3D modeling, and spatial computing. Through its flagship Map D and Eventdex platforms, Nextech3D.ai powers thousands of events annually with interactive floor mapping, registration, ticketing, mobile apps, AI matchmaking, and now, blockchain ticketing and accreditation.

For further information, please visit: www.Nextech3D.ai.

Investor Relations: investors@nextechar.com

Sign up for Investor News and Info – Click Here

Evan Gappelberg / CEO and Director
866-ARITIZE (274-8493)

Forward-looking Statements The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “will be” or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding the completion of the transaction are subject to known and unknown risks, uncertainties and other factors. There can be no assurance that such statements will prove to be accurate, as future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Nextech will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws

SOURCE: NexTech3D.AI Corp

View the original press release on ACCESS Newswire

Institute to Develop Novel Laser Fusion Reactor As Part of Japan’s Initiative to Pursue Challenging Concepts to Solve Issues Facing Future Society

PALO ALTO, CA / ACCESS Newswire / October 21, 2025 / The Director of the Blue Laser Fusion Energy Collaborative Research Institute, jointly established by Blue Laser Fusion Inc. (BLF) and the University of Osaka (UOsaka), has been selected as one of the Project Managers (PMs) for Japan’s prestigious Moonshot Research and Development Program (Moonshot Program) to develop an innovative fusion reactor using BLF’s novel laser technology. The project, led by Professor Shinsuke Fujioka of the High Energy Density Science Division in the UOsaka Institute of Laser Engineering (ILE), who also serves as Director of the BLF Energy Collaborative Research Institute, is a multi-year initiative focused on advancing BLF’s laser, target ignition, and reactor design with a goal of demonstration of a laser-based fusion energy generation system. The Institute will collaborate with other research partners, with the detailed project plan to be finalized in consultation with the Program Director and the Japan Science and Technology Agency (JST).

The Japan Science and Technology Agency (JST) implements the Moonshot Program, which is led by Japan’s Cabinet Office. The program pursues challenging R&D concepts set by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) in order to solve issues facing Japan’s future society. Moonshot Program Goal 10 is related to fusion energy: “Realization of a dynamic society in harmony with the global environment and free from resource constraints, through diverse applications of fusion energy….”

For additional information about Japan’s Moonshot program, see https://www.jst.go.jp/moonshot/en/program/goal10/index.html

The selection of the Director of the BLF Energy Collaborative Research Institute as a PM for Moonshot Program Goal 10 results from a highly competitive process led by JST and their external experts, including open calls and a review of a large number of applications, followed by multiple rounds of document and interview screening, culminating in final selection of a small number of university and corporate teams.

Dr. Shuji Nakamura, CEO of Blue Laser Fusion and 2014 Nobel Prize Winner, commented, “I am thrilled that Professor Fujioka, Director of the Blue Laser Fusion Energy Collaborative Research Institute at the University of Osaka, has been selected as Project Manager for Japan’s world-renowned Moonshot Program. We are pleased to collaborate with the University of Osaka, Japan’s leading laser fusion research and technology institution, as we work to accelerate the commercialization of laser-based fusion energy. BLF will continue to contribute, together with the University of Osaka, to solving Japan’s energy challenges.”

Blue Laser Fusion enabling technology innovations include a high efficiency, cost effective optical enhancement cavity (OEC) laser delivering megajoule class pulse energy at a high repetition rate, coupled with a high gain fuel target to achieve commercial fusion. Beyond the Moonshot Program selection, BLF has won US Department of Energy INFUSE projects in collaborations with Caltech and Colorado State University, and the company is a corporate partner in the US DOE IFE-Star RISE HUB for inertial fusion energy. Additionally, Blue Laser Fusion is on the industrial council for the US DOE FIRE Collaboratives led by General Atomics on fusion targets and by Idaho National Labs on fusion reactor design.

About Blue Laser Fusion, Inc.
Blue Laser Fusion Inc. (BLF) is a leading fusion energy company based in Santa Barbara, CA with offices in Silicon Valley and Tokyo, Japan. BLF was founded in 2022 by Dr. Shuji Nakamura, 2014 Nobel Laureate in Physics and solid-state lighting pioneer, whose high efficiency LED lighting inventions have helped transform the world by substantially reducing the global energy power consumption. The company is commercializing a proprietary and novel laser fusion technology to achieve the world’s first carbon-free, on demand, renewable, clean energy generation and to accelerate a transition to an electrified world. BLF aims to commercialize a GW scale reactor to provide power to the grid to meet the acute and increasing demand for clean energy for data centers and to support the AI revolution, for semiconductor chip fabrication facilities and chemical and steel production plants, as well as for electric vehicles and homes. The company has a comprehensive IP portfolio with more than 100 patents and applications internationally. To learn more, please visit: www.bluelaserfusion.com

About The University of Osaka Institute of Laser Engineering (ILE)
The Institute of Laser Engineering (ILE) at the University of Osaka, led by Director Ryosuke Kodama, is a world-leading research center for laser fusion and high-energy-density science. Originating from the Laser Engineering Research Facility under the School of Engineering, ILE has developed Japan’s largest high-power laser systems, including GEKKO XII and LFEX, and pioneered new academic fields such as laser astrophysics and plasma photonics. Designated by Japan’s Ministry of Education, Culture, Sports, Science and Technology (MEXT) as a Joint Usage/Research Center, ILE provides open access to researchers worldwide and drives innovation across science and industry. ILE and Blue Laser Fusion launched a joint research division in October 2023, directed by Professor Shinsuke Fujioka, and have since collaborated closely. In April 2025, the collaboration expanded into the Blue Laser Fusion Energy Collaborative Research Institute, further accelerating their joint efforts. The institute’s research focuses on developing high-average-power lasers, advancing clean fusion reactions, and evaluating technology and social acceptance for the societal implementation of fusion energy.
For more information, please visit: www.ile.osaka-u.ac.jp

Media contact:
Blue Laser Fusion Inc.
contact@bluelaserfusion.com

SOURCE: Blue Laser Fusion Inc.

View the original press release on ACCESS Newswire

CellRight announces Senior leadership changes, implementation of new commercial plan and cost reduction initiatives

SAN ANTONIO, TX / ACCESS Newswire / October 21, 2025 / CellRight Technologies, LLC, a specialist in regenerative osteoinductive bone scaffolds for patient implants, announces the following organisational changes, whilst remaining focussed on restoring Group revenue growth and profitability, and driving sustainable, long-term growth.

Jay LeCoque, newly appointed Executive Chairman of Tissue Regenix, has been appointed acting CEO and Executive Chairman, replacing Daniel Lee as Chief Executive Officer, who has left the Company. Jay brings extensive experience from his role as Executive Chairman of Source BioScience Limited, Commercial Director of Bioquell PLC, and CEO of Celsis International PLC and Limited. He has over 25 years of senior management experience in the global business development of UK listed and privately held life sciences companies. 

Kirsten Lund, former Tissue Regenix Group plc Finance Director from 2019 until 2022, and currently EMEA Business Director and Company Secretary, has been appointed to the Board as Chief Financial Officer. Kirsten has a mandate to implement strict financial controls across the business and a comprehensive review of the Group’s cost structure.

Following a restatement of year-end inventory and cost of sales for the financial year ended 31 December 2024, the Company’s new senior management team are initiating a $2m+ cost reduction initiative, to deliver improved Gross Margins and EBITDA performance. At the same time, a new commercial plan is being implemented to expand the direct sales and distribution footprint, and to secure further clinical data to strengthen claim support for the superiority of the Company’s products.

CellRight is based at a 13,650 sq ft facility in Universal City, San Antonio and processes all products that use the BioRinse^® and dCELL® processing platform. The Company’s patented decellularisation technology removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient’s body that can be used to repair diseased or damaged body structures.

Jay LeCoque, Executive Chairman and CEO of Tissue Regenix, commented: “Since joining the Group just 40 days ago on 7 September, we have undertaken significant changes to improve our financial, operational and commercial performance. I am aware that this restatement has caused some immediate concerns and our priorities remain focused on delivering a sustained recovery for the business. The Board remains confident that by executing on these plans, we can deliver on the Group’s potential to develop a great business that creates meaningful value for patients, customers and our shareholders.”

For more information:

Tissue Regenix Group plc	www.tissueregenix.com
Jay LeCoque, Executive Chairman	via Walbrook PR
Walbrook PR (Media Relations)	Tel: +44 (0)20 7933 8780 or TissueRegenix@walbrookpr.com
Alice Woodings / Paul McManus	Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893

About CellRight Technologies, LLC
CellRight Technologies, LLC is a full-owned subsidiary of Tissue Regenix Group plc: www.tissueregenix.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: CellRight Technologies, LLC

View the original press release on ACCESS Newswire

Unifying global IP rights and enabling up to $5 million in potential shareholder contributions, the agreement strengthens Telomir’s foundation for partnerships, licensing, and long-term value creation.

MIAMI, FLORIDA / ACCESS Newswire / October 21, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) (“Telomir” or the “Company”), a preclinical-stage biotechnology company developing therapies that target epigenetic drivers of cancer, aging, and age-related disease, today announced that it has executed a binding Letter of Intent (the “LOI”) to acquire TELI Pharmaceuticals, Inc., securing worldwide rights to its lead investigational therapy, Telomir-1.

The transaction aligns Telomir’s U.S. rights with TELI’s ex-U.S. intellectual property portfolio, which includes filings across Europe, Canada, Mexico, China, Japan, South Korea, India, Israel, Australia, Argentina, Uruguay, Taiwan, and the United Arab Emirates-creating a single global owner positioned to capture the full commercial value of Telomir-1 across oncology, metabolic, and age-related diseases.

Under the LOI, each outstanding share of TELI common stock will be exchanged for shares of TELO common stock, with the exchange ratio determined by an independent valuation. The transaction also includes up to $5 million in potential contributions, in cash or cash equivalents, from certain TELI shareholders over the duration of the collaboration – $1 million at closing, $2 million upon IND acceptance, and $2 million upon Phase 1/2 initiation – providing additional funding to advance development of Telomir-1. The transaction is subject to shareholder approval.

Why Worldwide Rights Expand Value

• Global oncology spend is accelerating: Cancer medicine spending reached $223 billion in 2023 and is projected to reach ~$409 billion by 2028; the U.S. represented roughly 45 percent ($99 billion in 2023) – meaning ex-U.S. markets now account for the majority of global oncology spend (IQVIA Global Oncology Trends 2024).

• Age-related and metabolic markets add further upside: The age-related macular degeneration (AMD) drug market totaled $10.8 billion in 2023 and is projected to grow to ~$18 billion by 2030 (Grand View Research 2024). Meanwhile, the global economic cost of diabetes, dementia, and neurodegenerative disease exceeds $2 trillion annually and continues to rise (IDF Diabetes Atlas 2023; Alzheimer’s Disease International 2023).

• Investor takeaway: With worldwide rights, Telomir can now pursue global or regional partnerships, out-licensing, or asset-sale opportunities across markets where ex-U.S. demand exceeds U.S. demand – enhancing strategic flexibility and long-term enterprise value.

CEO Commentary

Erez Aminov, Chief Executive Officer of the Company, stated:

“Executing this binding LOI to secure worldwide rights transforms Telomir-1 from a U.S.-focused asset into a global platform. Strategically, it gives us cleaner access to partnership, licensing, or even asset sale opportunities across continents. Economically, the addressable market outside the United States is larger than inside it. We believe this unified structure positions Telomir for significant long-term value creation as we continue advancing our epigenetic and longevity programs.”

Dr. Itzchak Angel, Chief Scientific Advisor of the Company, added:

“This global alignment enables us to plan development for true worldwide impact. It streamlines our path to explore Telomir-1 in oncology, metabolic, and degenerative diseases such as breast and pancreatic cancer, AMD, Progeria, Wilson’s disease, and Type 2 diabetes, where our preclinical data already show compelling functional restoration.”

Scientific and Market Context

Telomir-1 is an investigational oral small-molecule epigenetic therapy designed to reset abnormal DNA methylation patterns, stabilize telomeres, and restore proper gene regulation – addressing the root biological causes of cancer, aging, and degenerative disease rather than their downstream symptoms.

Across multiple preclinical models, Telomir-1 has shown activity at the intersection of epigenetic control, DNA methylation balance, telomere maintenance, metal regulation, and mitochondrial health – five cellular processes central to both oncologic and age-related disorders.

Representative findings include:

• Oncology:

  • In triple-negative breast (TNBC) and pancreatic cancer models, Telomir-1 produced a dose dependent loss of cancer-cell viability through iron-dependent mitochondrial and energy-pathway modulation.

  • In prostate cancer, Telomir-1 reversed abnormal DNA methylation of tumor suppressor genes MASPIN, RASSF1A, and STAT1, reactivating natural anti-metastatic defenses.

• Age-Related Macular Degeneration (AMD): Telomir-1 restored retinal structure and vision in a validated zebrafish model, demonstrating neuroprotective and regenerative effects.

• Progeria & Werner Syndrome: In patient-derived Progeria (HGPS) cells, Telomir-1 normalized oxidative stress and mitochondrial instability. In nematode and zebrafish models of Werner-like accelerated aging, it extended lifespan, lengthened telomeres, reversed muscle degeneration, and reset molecular-age markers.

• Wilson’s Disease: In a genetic ATP7B-deficient (C271X⁻/⁻) zebrafish model, Telomir-1 produced dose-dependent restoration of neurological, hepatic, and renal function, reducing tremors four- to five-fold, halving hepatic copper accumulation, reversing liver and kidney pathology, normalizing ALT, AST, and bilirubin, and improving survival under copper stress.

• Type 2 Diabetes: In a zebrafish model of Type 2 diabetes mellitus, Telomir-1 reversed hyperglycemia and insulin resistance to near pre-diabetic levels, significantly reduced HOMA-IR values, improved oral glucose tolerance, and increased survival. Mechanistically, Telomir-1 appears to normalize iron metabolism and reduce oxidative stress in pancreatic beta cells, directly addressing the root cause of insulin resistance.

• Longevity & Healthspan: Using microfluidic C. elegans aging models developed with Nagi Bioscience SA, Telomir-1 extended lifespan, improved mobility, and reversed biological age markers, confirming its potential to enhance both longevity and healthspan.

Collectively, these data position Telomir-1 as a potential first-in-class DNA methylation reset and telomere stabilizing therapy with multi-system regenerative potential.

From a commercial perspective, unifying worldwide rights enables Telomir to access multi-hundred-billion-dollar opportunities. Global oncology spending alone is projected to exceed $400 billion by 2028 (IQVIA 2024), while the combined markets for AMD, diabetes, and neurodegenerative diseases surpass $1 trillion annually.

Key LOI Terms (Summary)

• Structure: Stock-for-stock acquisition; exchange ratio determined by independent valuation.

• Shareholder Contribution: A potential for up to $5 million in cash or cash equivalents over the duration of the collaboration- $1 million at closing; $2 million upon IND acceptance; $2 million upon Phase 1/2 initiation. Milestone shares allocated but not issued until funded.

• Lockup: TELI shareholders subject to a six-month lockup on shares received.

• Closing: Not contingent on milestone payments; subject to customary board, stockholder, regulatory, and due diligence conditions.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a preclinical-stage biotechnology company developing small-molecule therapies that target epigenetic drivers of cancer, aging, and age-related disease. Its lead candidate, Telomir-1, has demonstrated the ability to reset DNA methylation, stabilize telomeres, inhibit histone demethylases, and restore cellular energy and metabolic balance across multiple preclinical models. For more information, visit www.telomirpharma.com.

Cautionary Note Regarding Forward-Looking Statements

This press release, statements of Telomir’s management or advisors related thereto, and the statements contained in the news story linked in this release contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.

Any forward-looking statements in this press release are based on Telomir’s current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir’s programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which are on file with the SEC and available at www.sec.gov. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Helga Moya
info@telomirpharma.com
(786) 396-6723

SOURCE: Telomir Pharmaceuticals, Inc

View the original press release on ACCESS Newswire

Global Sales Leader to Drive Unified Strategy and Accelerate Customer-Centric Growth

NEW YORK CITY, NY / ACCESS Newswire / October 21, 2025 / Foundry, the leading global tech media, data, and marketing services company, is thrilled to announce the appointment of Gregory Anderson as Global Chief Revenue Officer (CRO). With two decades of proven success driving sales performance across technology and media sectors, Anderson joins Foundry with a clear focus on enhancing the buyer journey and accelerating strategic growth globally.

Anderson joins Foundry from Informa TechTarget, where he most recently served as Chief Sales Officer at Omdia. During his tenure, he held several other key leadership roles, including positions leading sales and the integration of major acquisitions such as BrightTALK and Enterprise Strategy Group (ESG). He also spent eight years as VP of Sales for APAC at Informa TechTarget, where he helped expand regional operations.

“We are thrilled to welcome Greg to the Foundry team as our new CRO,” said Mike Finnerty, CEO of Foundry. “Greg brings a wealth of experience and a strong track record in our industry, making him uniquely positioned to build on the momentum we’ve created. His leadership will be instrumental in strengthening our connection with the world’s most influential IT leaders and helping them make informed purchasing decisions.”

As B2B marketing evolves toward more human and personalized data-driven engagement, Foundry remains committed to helping technology companies connect with buyers in meaningful ways. By combining intent data with powerful storytelling, Foundry delivers experiences that resonate with buyers’ unique needs, foster trust, and build valuable relationships.

“I’m inspired by the opportunity to help shape Foundry’s next chapter alongside Mike and with the support of Regent, which truly understands the value of trusted editorial brands,” said Greg Anderson, Global Chief Revenue Officer of Foundry. “This role brings me back to what I love – partnering with technology marketers to connect their brands with buyers through trusted editorial channels. With Foundry’s respected voices and unique blend of digital and in-person communities, we’re positioned to be a reliable resource in a time of growing AI-driven misinformation. I’m excited to work with the team to uncover new growth opportunities and deliver solutions that help vendors reach, inform, and build trust with decision-makers.”

To learn more about Foundry’s technology marketing and buyer engagement solutions, please visit: foundryco.com.

About Foundry

Foundry helps companies bring their visions to reality through a combination of media, marketing technologies and proprietary data on a global scale. Our platforms are powered by data from an owned and operated ecosystem of global editorial brands, awards, and events, all engineered and integrated to drive marketing campaigns for technology companies.

Foundry is one of the world’s leading tech media, data and marketing services companies, and is the proud owner of the global tech sector’s most revered media brands – CIO, Computerworld, CSO, InfoWorld, Macworld, Network World, PCWorld, Tech Advisor and TechHive. To learn more, visit  foundryco.com.

Ameera McNeal, Marketing Director
Ameera_mcneal@foundryco.com
914-610-0221

SOURCE: Foundry

View the original press release on ACCESS Newswire